✅ This trial is currently recruiting volunteers
If you think you might be eligible, speak to your GP or specialist about this trial before applying.
Status
Recruiting
Phase
PHASE3
Participants
ALL
Age Range
12 Years – 80 Years
About This Trial
The objective of this study is to assess the potential for GB-0895 treatment to improve the health of adolescents and adults with severe asthma that is uncontrolled by inhaled corticosteroids (ICS) and conventional asthma controllers.
The study details include:
Study treatment: randomized to receive either GB-0895 or placebo administered every 6 months over 52 weeks.
Visit frequency: every 1-2 months after the first month.
Who Can Join?
1. Adults and adolescents ≥ 12 and ≤ 80 years of age. 2. Documented physician diagnosis of asthma for ≥ 2 years. 3. Subjects must be on medium to high dose ICS for ≥ 12 months before Screening Visit 1 plus at least 1 additional asthma controller (e.g., LABA, LAMA) ≥ 3 months before Screening Visit 1 with no change in ICS or controller(s) for at least three months. 4. Subjects must have a well-documented history of at least two asthma exacerbations requiring systemic corticosteroid treatment despite the use of medium-to-high dose ICS in the past 12 months before Screening Visit 1. 5. Adults ≥ 18 years of age at Screening Visit 1, a pre-BD FEV1
⚠ Always speak to your doctor before applying to any clinical trial.
More Lung & Breathing Trials
Recruiting PHASE2
Trial Comparing the Safety and Efficacy of Two Different Oral VPV Doses With Placebo…
Recruiting PHASE3Roll-over Study for Participants Who Have Completed a Previous Clinical Study With Benralizumab (Fasenra)…
Recruiting PHASE2A Study of KT-621 Administered Orally to Adult Participants With Moderate to Severe Eosinophilic…